Zacks Investment Research Downgrades Bayer AG (BAYRY) to Hold

Zacks Investment Research Downgrades Bayer AG (BAYRY) to Hold


According to Zacks, "Bayer's revenues during the third quarter of 2015 were boosted by its newly launched pharmaceutical products. These products are expected to continue their strong run in the upcoming quarters as well.



from Biotech News